251 related articles for article (PubMed ID: 21737767)
21. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
22. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
23. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
Benes H
Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
[TBL] [Abstract][Full Text] [Related]
24. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
25. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial.
Walters AS; Ondo WG; Kushida CA; Becker PM; Ellenbogen AL; Canafax DM; Barrett RW;
Clin Neuropharmacol; 2009; 32(6):311-20. PubMed ID: 19667976
[TBL] [Abstract][Full Text] [Related]
26. A comparison of sustained-release bupropion and placebo for smoking cessation.
Hurt RD; Sachs DP; Glover ED; Offord KP; Johnston JA; Dale LC; Khayrallah MA; Schroeder DR; Glover PN; Sullivan CR; Croghan IT; Sullivan PM
N Engl J Med; 1997 Oct; 337(17):1195-202. PubMed ID: 9337378
[TBL] [Abstract][Full Text] [Related]
27. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Montplaisir J; Karrasch J; Haan J; Volc D
Mov Disord; 2006 Oct; 21(10):1627-35. PubMed ID: 16874755
[TBL] [Abstract][Full Text] [Related]
28. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
[TBL] [Abstract][Full Text] [Related]
29. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
30. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Moss EL; Simpson JS; Pelletier G; Forsyth P
Psychooncology; 2006 Mar; 15(3):259-67. PubMed ID: 16041840
[TBL] [Abstract][Full Text] [Related]
31. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.
Grote L; Leissner L; Hedner J; Ulfberg J
Mov Disord; 2009 Jul; 24(10):1445-52. PubMed ID: 19489063
[TBL] [Abstract][Full Text] [Related]
33. Bupropion as a possible treatment option for restless legs syndrome.
Lee JJ; Erdos J; Wilkosz MF; LaPlante R; Wagoner B
Ann Pharmacother; 2009 Feb; 43(2):370-4. PubMed ID: 19193596
[TBL] [Abstract][Full Text] [Related]
34. Comparison of pregabalin with pramipexole for restless legs syndrome.
Allen RP; Chen C; Garcia-Borreguero D; Polo O; DuBrava S; Miceli J; Knapp L; Winkelman JW
N Engl J Med; 2014 Feb; 370(7):621-31. PubMed ID: 24521108
[TBL] [Abstract][Full Text] [Related]
35. Bupropion may improve restless legs syndrome: a report of three cases.
Kim SW; Shin IS; Kim JM; Yang SJ; Shin HY; Yoon JS
Clin Neuropharmacol; 2005; 28(6):298-301. PubMed ID: 16340389
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of restless legs syndrome in adult Saudis attending primary health care.
BaHammam A; Al-shahrani K; Al-zahrani S; Al-shammari A; Al-amri N; Sharif M
Gen Hosp Psychiatry; 2011; 33(2):102-6. PubMed ID: 21596202
[TBL] [Abstract][Full Text] [Related]
37. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Jorenby DE; Leischow SJ; Nides MA; Rennard SI; Johnston JA; Hughes AR; Smith SS; Muramoto ML; Daughton DM; Doan K; Fiore MC; Baker TB
N Engl J Med; 1999 Mar; 340(9):685-91. PubMed ID: 10053177
[TBL] [Abstract][Full Text] [Related]
38. Pilot trial of onabotulinumtoxina (Botox) in moderate to severe restless legs syndrome.
Agarwal P; Sia C; Vaish N; Roy-Faderman I
Int J Neurosci; 2011 Nov; 121(11):622-5. PubMed ID: 21740308
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
40. A bupropion smoking cessation clinical trial for cancer patients.
Schnoll RA; Martinez E; Tatum KL; Weber DM; Kuzla N; Glass M; Ridge JA; Langer C; Miyamoto C; Wileyto EP; Leone F
Cancer Causes Control; 2010 Jun; 21(6):811-20. PubMed ID: 20087643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
